Why the study?
This study evaluates the therapeutic efficacy of adeno-associated viruses in treating neurodegenerative lysosomal storage diseases such as metachromatic leukodystrophy.
Answers are grounded in this paper and cite their sources.
This preclinical study evaluates the biodistribution and safety of AAV9 and AAVrh.10 vectors encoding ARSA in pigs with prior AAV9 immunization, providing insights for gene therapy in metachromatic leukodystrophy.
Lysosomal storage diseases are a group of inherited disorders caused by lysosomal dysfunction, impairing cellular metabolic enzymes, signaling pathways, and other biological processes. Among them is metachromatic leukodystrophy (MLD) associated with arylsulfatase A (ARSA) deficiency, which leads to the accumulation of sulfatides and the destruction of myelin sheaths in the nervous system. This study evaluates the therapeutic efficacy of adeno-associated viruses (AAVs) in treating neurodegenerative diseases such as MLD. The biodistribution and safety of AAV9-ARSA and AAVrh.10-ARSA vectors following prior immunization in pigs were shown. The immune aspects of AAV-based gene therapy were outlined. Its potential efficacy and durability limitations were discussed.
No takes yet. Share an insight, caveat, or question.
Mullagulova et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: